Kornimate/medical-research-clean huggingface dataset:
efficacy and safety of stbf photodynamic therapy for moderate and severe acne vulgaris

Conditions: Acne

Summary: this study is being done to evaluate the efficacy and safety of shengtaibufen photodynamic therapy (stbf-pdt) for treatment of moderate or severe acne vulgaris.

this study is a split randomized controlled trial and being done to evaluate the efficacy and safety of shengtaibufen photodynamic therapy (stbf-pdt) for treatment of moderate or severe acne vulgaris.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosed with moderate to severe acne; 2. male and female patients of age between 18-30 years old ; 3. all patients read the instructions of the subject, willing to follow the program requirements; 4. no other topical treatment received within 2 weeks prior to enrollment; 5. no systemic treatment was given within 4 weeks prior to enrollment; 6. patients were unsuitable for surgery for various reasons,unwilling to undergo surgery, and signed informed consent when they had informed other alternatives and agreed to take pictures of the lesion. exclusion criteria: 1. those who did not complete the informed consent; 2. the lesions belongs to any of the following conditions: there is damage and inflammation, which may lead to the drug entering the open wound; 3. patients with skin photoallergic diseases, porphyria; 4. known to have a history of allergies to test drugs (porphyrins) and their chemically similar drugs; 5. patients with other obvious diseases that may affect the evaluation of efficacy; 6. scars or patients with a tendency to form scars; 7. known to have severe immune dysfunction, or long-term use of glucocorticoids and immunosuppressants; 8. severe heart, liver, kidney disease; with hereditary or acquired people with sexual coagulopathy 9. those with severe neurological, psychiatric or endocrine diseases; (10)women who are pregnant, breast-feeding or using inappropriate contraceptives; those with a history of drug abuse; those who have participated in other drug clinical trials within 4 weeks before treatment.

Keywords: acne photodynamic therapy shengtaibufen efficacy safety
artificial intelligence to strategically enhance pulmonary embolism response team activation

Conditions: Pulmonary Embolism Subacute Massive

Summary: pulmonary embolism (pe) remains a high mortality and morbidity disease state. the investigators have previously shown that use of a pulmonary embolism response team (pert) can improve overall readmission, bleeding, and mortality outcomes. unfortunately, pert may still be underutilized from a national standpoint and may not be readily available in underserved areas. the use of artificial intelligence (ai) may help streamline and systematically ensure unbiased mechanism for activation of pert for discussion of patients with siginficant clot burden and hemodynamic abnormalities. ai algorithms have been fda approved for use of triage of the pe patient. the institutional pert program will adapt the use of an ai algorithm for activation as routine care; the efficiency of activation will be compared to our retrospective historical comparison for efficiency and appropriateness of activation. the active phase of the study is designed to further differentiate between patients who are considered to be intermediate-high risk category but yet do not clearly qualify for invasive therapy (catheter-directed therapy, systemic thrombolysis, or invasive hemodynamic support). these patients will undergo walking test to further understand noninvasive hemodynamic compromise and undergo 2:1 randomization to early-invasive strategy versus mtranditional medical therapy.


Eligibility criteria:
inclusion criteria: * patients obtaining a ct at university hospitals found to have a pulmonary embolism with evidence of right ventricular strain (rv:lv \> 0.9) along with an abnormal vital sign (hr \> 110 bpm, rr \> 30/min, sbp \< 100 mmhg, or o2 saturation \< 90%) * patients undergoing pert discussion as deemed appropriate by the provider exclusion criteria: * age \<18 * pregnant patients. women of childbearing age will be asked if they are pregnant before enrollment. no formal pregnancy test will be performed as a part of this study. if a patient does require invasive intervention, as part of the routine procedure for cardiac catheterization laboratory, women of childbearing age will either undergo pregnancy testing or opt-out per their own discretion * patients unable to perform 6mwt (e.g., lack of one or both legs) will not be included in the randomization. they will be included in the observation for routine treatment

Keywords: pert artificial intelligence
the effectiveness of guided imagery for a nonprofit's employees

Conditions: Focus of Study; Stress

Summary: primary aim a. to determine if listening to prerecorded guided imagery 3 times per week for 4 weeks will reduce state anxiety, perceived stress, burnout, compassion fatigue, and vicarious trauma in fronltine service staff. primary aim b. to determine if staff will continue to listen to guided imagery after the first 4 weeks of the study is over.

the purpose of this study is to compare the change in stress levels of employees who listen to prerecorded guided imagery to employees who take breaks, and to determine if employees are likely to adopt prerecorded guided imagery as a self-care tool. participants will be randomly assigned to either the guided imagery group or the control group. members of the control group will be asked to take a 10 minute break 3 times per week for 4 weeks. members of the guided imagery group will be asked to listen to one prerecorded guided imagery track 3 times per week for 4 weeks. all participants will fill out questionnaires before and after the 4 week period. all participants will fill out a short form before and after listening to each guided imagery, or before and after taking each break. phase 2: after phase 1 is complete, all participants will have the option to participate in phase 2 of the study. during phase 2, participants will receive a calendar and put a mark on every day that they listen to a guided imagery track. at the end of 4 weeks, participants will turn in the calendar.

Eligibility criteria:
inclusion criteria: * staff of a nonprofit who work a minimum of three shifts per week * willing and able to use about 8-15 minutes of their lunch hours three times per week for for four weeks for the study exclusion criteria: * staff members will be excluded from the study if they currently listen to guided imagery * those currently experiencing drug or alcohol abuse, suicidal ideation, or other serious mental health issue while not under the care of a trained mental health professional will also be excluded

Keywords: guided imagery burnout compassion fatigue state anxiety
phenotypic clinical, and genetic characteristics of patients with nontuberculosis mycobacteria

Conditions: Nontuberculosis Mycobacterial Lung Disease

Summary: the purpose of this study is to elucidate phenotypic, clinical, and genetic characteristics of korean nontuberculosis mycobacteria (ntm) patients.

to elucidate phenotypic, clinical, and genetic characteristics of korean ntm patients. especially, to compare body mass index, positive rate of igra, and cftr mutation with general korean population.

Eligibility criteria:
inclusion criteria: * persons met diagnostic criteria of ntm lung disease by ats/idsa on 2007 exclusion criteria: * already on treatment for ntm lung disease * appropriate exclusion of other lung diagnosis

Keywords: ntm lung disease ntm lung disease patients enrolled in snuh
prenatal surgical repair of fetal myelomeningocele

Conditions: Foetus With Myelomeningocele

Summary: the open surgical repair of myelomeningoceles before 26 weeks gestational age provides a correction of the anomaly of chiarri, reduces the incidence of ventriculomegaly (defined as a measure of the ventricles at the crossroads ≥ 10 mm), and get a lower of injury than one corresponding to the anatomical defect (as defined by the last upper normal vertebra before the defect). the purpose of this study is to introduce in france an innovative technique for prenatal repair of myelomeningocele until now developed only on the american continent.

spina bifida (sb) represents one of the most severe congenital malformation of the central nervous system and amenable to prenatal diagnosis. in the past 20 years, prenatal repair of sb has become an established technique. the prium study will include 10 cases of fetuses with prenatal diagnosis of sb and for whom the maternal willing will be to continue the pregnancy. a surgical prenatal repair of the defect will be planed at 19-25+6 weeks gestation following maternal laparotomy and hysterotomy under maternal general anesthesia. the delivery will be planed at 36 weeks'. postnatal evaluation of the neonates will be scheduled at birth, 1 month, 12 months and 36 months of age. those data will be matched to controls who have underwent a conventional postnatal repair of the sb

Eligibility criteria:
inclusion criteria: * patient of majority age, with an assumption by health insurance, understanding and speaking french * a term between 19 and 25 +6 weeks gestational age (not for control) * single-pregnancy * normal fetal karyotype * myelomeningocele with higher-level defect between s1 and t1 * placenta not low-inserted or not covering * fault-isolated ultrasound reference exclusion criteria: * age under 18 years * patient foreigner who understands not french * multiple pregnancy * low placenta inserted or covering * severe kyphosis * placental abruption * fetal malformation unrelated to the existence of myelomeningocele (the existence of a malposition of one or both feet do not represent an exclusion criterion) * increased risk of preterm birth: a history of preterm delivery before 37 weeks gestational age, cervical length \<26 mm before 26 weeks gestational age (not for control) * bleeding active between 20 and 26 weeks gestational age (not for control) * maternal obesity with bmi\> 35 (not for control) * history of uterine surgery involving the anterior surface of the uterus (not for control) * maternal contradiction in surgery or general anesthesia (not for control)

Keywords: myelomeningocele arnold chiari malformation spina bifida
clinical study of [18f] pm-pbb3 pet imaging of tau protein in neurodegenerative diseases

Conditions: Neurodegenerative Diseases

Summary: in terms of the diagnostic technology of brain neurodegenerative diseases, the injection of positron tracers into the human body, so that it can combine with the corresponding protein, and show its distribution through pet imaging is a mature technology in the industry. at present, several research groups around the world are working on the development and clinical efficacy evaluation of their respective tau imaging agent compounds.this clinical research project intends to display the abnormal changes of tau protein in living brain through \[18f\]pm-pbb3 pet imaging, which is a second-generation tracer further optimized on the basis of \[11c\]pbb3, and has the advantages of closer binding to tau protein entanglement and less non-specific binding than similar imaging agents. better image quality and a wider range of clinical applications.


Eligibility criteria:
inclusion criteria: * between 45 and 90 years old; no gender limitation. brain mri supported the diagnosis of neurodegeneration, and there was no evidence of other neurological diseases. informed consent signed in person by the subject or his legal guardian or caregiver. exclusion criteria: * have other serious neurological disorders, or gastrointestinal, cardiovascular, liver, kidney, blood system, tumor, endocrine, respiratory, immune deficiency, and other serious diseases. received an experimental drug or device within 1 month (whose efficacy or safety is unclear). patients who were unwilling to undergo pet/ct scans. pregnancy.
augmented reality-based telerehabilitation platform for patients with stroke

Conditions: Stroke

Summary: the study is to 1) determine the feasibility of the use of our augmented reality (ar) rehabilitation program, including its preliminary efficacy, 2) determine the feasibility of obtaining an augmented reality assessment based on the fugl-meyer assessment - upper extremity (fma-ue).


Eligibility criteria:
inclusion criteria: 1. 18 years or older 2. ≥3 months post ischemic or hemorrhagic stroke 3. upper extremity deficit with an fma-ue score between 20-50 4. able to operate the ar device independently or with the help of a caregiver 5. sufficiently proficient in the english language to follow instructions from reia exclusion criteria: 1. history of developmental, neurological or psychological impairment leading to functional disability 2. vision or visual field impairment that interferes with the use of the ar headset 3. severe photosensitivity that makes use of the ar headset uncomfortable 4. history of visually provoked seizures 5. hearing aids 6. cardiac pacemaker 7. implantable cardioverter-defibrillator (icd)
study il- 35 level and fibronectin type ⅲ domain containing protein 5 \ irsin (fndc5 rs3480) gene variations in chronic hepatitis b.

Conditions: Hepatitis B, Chronic

Summary: find a possible association between fibronectin type ⅲ domain containing protein 5 \\ irsin (fndc5 rs3480) gene single nucleotide polymorphism with chronic hepatitis b and the distribution of its alleles, in relation to many clinical parameters of the chronic hepatitis b group. * asses the correlation between il-35 serum level and the risk of chronic hepatitis b. * asses the correlation between sod serum level and the risk of chronic hepatitis b.

hepatitis b virus (hbv) infection is a serious public health problem worldwide, with approximately 2 billion people having a history of hbv infection and 350 million of them suffering from chronic hbv infection (1). although the host factors (such as infection age, gender and immune status), viral and environmental factors are thought to be involved in affecting the development of chb. the mechanisms underlying the different clinical outcomes of hbv infection have not been fully understood. studies indicated that host genetic factors play a critical role in the development of hbv infection, especially single nucleotide polymorphisms (snps), is regarded to be one of the determinants for this clinical heterogeneity(2,3). some polymorphisms have been reported to be involved in susceptibility to chb in disease severity and progression, or disease prognosis (4,5). irisin is encoded by the fndc5 gene, whose expression is controlled by the peroxi- some proliferator activated receptor gamma coactivator 1 alpha (pgc-1α). pgc-1α is a transcriptional co-activator which does not bind directly to dna. studies indicated that the estrogen-related receptor alpha (errα) could be a factor that plays a role in pgc-1α binding to dna. errα is encoded by the esrra gene and is an orphan nuclear receptor, which has two domains. one of them allows the interaction with dna, and the second one with a ligand. the errα structure is similar to that of the estrogen receptor alpha (erα), but this receptor does not bind to natural estrogens. errα interacts with a canonical sequence of the estrogen response elements (erre). errα and erα could compete with each other to bind to similar dna elements. together, errα binds to dna, in complex with pgc-1α, to regulate the activity of genes such as fndc5 (6).

Eligibility criteria:
inclusion criteria: * patients diagnosed as a clinical disease of chb according to the diagnostic criteria of chb based on, hbsag, hbeag serostatus ,hbv dna level, biochemical liver function, and ultrasonography exclusion criteria: * the chronic hbv patients on antiviral therapy will be excluded.
application of ctdna in the evaluation of curative effect and prognosis of sclc patients

Conditions: Small Cell Lung Cancer Extensive Stage

Summary: the purpose of this study is to evaluate the application value of circulating tumor dna(ctdna) with efficacy evaluation and prognostic assessment in patients with unresectable sclc, who were receiving radiotherapy and chemotherapy treatment.

1. according to each point in time of ctdna, to analyze the dynamic changes of tumor burden and clonal subtypes which to evaluate the application value of ctdna in curative efficacy evaluation. 2. compare the two time points before and after radiotherapy and chemotherapy treatment of the cell free dna (cfdna) concentration and tumor burden, analysis the correlation between the changes and prognosis.

Eligibility criteria:
inclusion criteria: * provision of informed consent； * newly diagnosed and histological or cytological confirmed extensive stage small cell lung cancer; * all indicators has confirmed and allow to receive radiotherapy and chemotherapy; * follow-up can be carried out and the peripheral blood samples can be collected; * cooperate with the provision of clinical pathological data required by the research. exclusion criteria: * patients have other primary cancers; * patients unable to cooperate with the study for follow-up according to the determined clinical follow-up cycle; * unable to accept the judgment of curative effect evaluation by the designated methods such as ct.
trans-rectal focal microwave ablation of the index tumor in patients with low-risk prostate cancer

Conditions: Low-Risk Prostate Cancer

Summary: the purpose of this study is to determine if trans-rectal microwave ablation of the index tumor of patients with low-risk prostate cancer is sufficiently precise and safe, using mri-transrectal ultrasound image registration.

in men with low-risk prostate cancer, european and american guidelines recommend either active surveillance or whole-gland treatments, with significant induced morbidity and burden on quality of life. focal treatments of the index tumor are currently under investigation to decrease morbidity while proposing active treatment. the purpose of this study is to determine the feasibility, precision and safety of a novel ablation treatment using microwaves, delivered transrectally under real-time guidance with mri-transrectal ultrasound image registration. the index tumor will be detected with prostate mri and characterized with targeted biopsies using mri-transrectal ultrasound image registration. it will then be ablated with microwaves using the same transrectal approach and guidance system (koelis).

Eligibility criteria:
inclusion criteria: * patients aged from 45 to 76 years old ; * life expectancy above 10 years ; * diagnosis of prostate cancer confirmed on prostate biopsies ; * low risk of progression, defined with d'amico criteria : * t1c or t2a stage * maximum gleason score of 3+4, including targeted biopsies corresponding to less than 50% grade 4 for the tumor * prostate specific antigen \<15 ng/ml * detection of the index tumor with prostate mri, characterized with targeted biopsies using mri-transrectal ultrasound image registration ; * patient accepting to be followed after the procedure using active surveillance protocol standards ; * patient affiliated to national health care insurance ; * free consent, informed and written, dated and signed by the patient and the investigator before enrollment. exclusion criteria: * medical past history of prostatic surgery ; * medical past history of radiotherapy or pelvic trauma ; * medical past history of acute or chronic prostatitis * severe bph-related urinary tract symptoms defined as an ipss \>18 ; * extra-capsular extension or seminal vesicle invasion on prostate mri. * tumor involvement \> 3 mm on systematic biopsies outside the tumor volume detected on mri. * tumor largest axis \> 20 mm on prostate mri ; * distance of less than 5 mm between the tumor and the rectum * patient unable to understand the course of the study * history of allergy or non-tolerance to gadolinium salts used in mri * patient with a contraindication to performing an mri * person placed under safeguard of justice

Keywords: cancer prostate psa biopsies microwave trans rectal focal treatment
clareon panoptix pro vs. clareon panoptix - study a

Conditions: Aphakia; Presbyopia

Summary: the purpose of this study is to evaluate the safety and effectiveness of clareon™ panoptix™ pro trifocal intraocular lens (iol) compared to clareon™ panoptix™ trifocal iol.

subjects will attend 9 scheduled study visits for a total individual duration of participation of approximately 7 months. the primary endpoint will be assessed at the month 2 follow-up visit. both eyes of a subject must qualify for enrollment into this study.

Eligibility criteria:
key inclusion criteria: * understand and sign an ethics committee-approved informed consent form; * willing and able to attend all scheduled study visits as required by the protocol; * planned cataract surgery (both eyes); * preoperative corneal astigmatism less that 1.00 diopter in each eye. * other protocol-defined inclusion criteria may apply. key exclusion criteria: * women of childbearing potential if currently pregnant, intend to become pregnant during the study, or are breastfeeding; * ocular conditions as specified in the protocol; * subjects who desire monovision correction. * other protocol-defined exclusion criteria may apply.

Keywords: cataract iol
high-resolution magnetic resonance imaging of intracranial atherosclerotic plaques in ischemic stroke

Conditions: Stroke; Intracranial Atherosclerosis; High Resolution Magnetic Resonance Imaging

Summary: intracranial atherosclerotic disease is the most common cause of ischemic stroke in asia, also in china. currently, despite vascular recanalization therapy, statins are one of the main drug choices for treating atherosclerotic plaque. high resolution magnetic resonance imaging (hrmri) can accurately assess the status of intracranial and extracranial arterial plaque, and has high consistency with histopathology. thus, hrmri technology has been widely used to monitor the efficacy of drug treatment for atherosclerotic plaque in clinical trials or practice. as a non-invasive technique, hrmri make it possible to assess the morphologic characteristics of vascular wall and plaque composition of intracranial artery in vivo. it can quantitative analysis including components such as lipid-rich necrotic core, fiber cap thickness, intra-plaque hemorrhage, calcification, etc. therefore, it is crucial for evaluating the etiology of ischemic stroke and developing secondary prevention strategies. at present, there is a lack of large-scale and prospective study to evaluate the etiology of ischemic stroke including cryptogenic stroke based on hrmri. in this context, this study aims to establish a multi center hrmri database of intracranial arteries among chinese patients with ischemic stroke.


Eligibility criteria:
inclusion criteria: * 1. patient age ≥40 years * 2. time of stroke onset: within 2 week * 3. baseline nihss score ≤16 * 4. ischemic stroke confirmed by head ct or mri * 5. premorbid mrs ≤1 * 6. the degree of stenosis of extracranial arteries including internal carotid artery, vertebral artery on the lesion side ≤50% * 7. the culprit plaque or possible culprit plaque with plaque burden of 40% or more found by hrmri in the proximal part of the middle cerebral artery m1 segment or basilar artery of ipsilateral lesion * 8. signed informed consent exclusion criteria: * 1. intracranial hemorrhage found by head ct * 2. had a contraindication to mri,or could not complete required mri sequences * 3. intracranial tumor, arteriovenous malformation, or aneurysm * 4. comorbidity with any serious diseases and life expectancy is less than one year * 5. pregnancy * 6. patients not suitable for this clinical studies considered by researcher